Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy
International Journal of Molecular Sciences · 24.09.2024 · 25 (19) · 10255
DOI: 10.3390/ijms251910255 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.09.2024. Verfasst von Patricia Guevara-Ramírez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Genética y Genómica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito 170129, Ecuador. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Hematologic Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad UTE-Ecuador.
Abstract (Originalsprache)
Hematologic malignancies (HMs), including leukemia, lymphoma, and multiple myeloma, involve the uncontrolled proliferation of abnormal blood cells, posing significant clinical challenges due to their heterogeneity and varied treatment responses. Despite recent advancements in therapies that have improved survival rates, particularly in chronic lymphocytic leukemia and acute lymphoblastic leukemia, treatments like chemotherapy and stem cell transplantation often disrupt gut microbiota, which can negatively impact treatment outcomes and increase infection risks. This review explores the complex, bidirectional interactions between gut microbiota and cancer treatments in patients with HMs. Gut microbiota can influence drug metabolism through mechanisms such as the production of enzymes like bacterial β-glucuronidases, which can alter drug efficacy and toxicity. Moreover, microbial metabolites like short-chain fatty acids can modulate the host immune response, enhancing treatment effectiveness. However, therapy often reduces the diversity of beneficial bacteria, such as Bifidobacterium and Faecalibacterium, while increasing pathogenic bacteria like Enterococcus and Escherichia coli. These findings highlight the critical need to preserve microbiota diversity during treatment. Future research should focus on personalized microbiome-based therapies, including probiotics, prebiotics, and fecal microbiota transplantation, to improve outcomes and quality of life for patients with hematologic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Investigación Genética y Genómica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito 170129, Ecuador.
- Escuela de Enfermería, Facultad de Ciencias de la Salud, Universidad de Las Américas, Quito 170124, Ecuador.
- Grupo de Bio-Quimioinformática, Universidad de Las Américas, Quito 170124, Ecuador.
ORCID-Profile: Patricia Guevara-Ramírez, Santiago Cadena-Ullauri, Viviana A Ruiz-Pozo, Rafael Tamayo-Trujillo, Alejandro Cabrera-Andrade, Ana Karina Zambrano
Förderung
- Universidad UTE-Ecuador
Zitieren
APA
Guevara-Ramírez, P., Cadena-Ullauri, S., Paz-Cruz, E., Ruiz-Pozo, V. A., Tamayo-Trujillo, R., Cabrera-Andrade, A., & Zambrano, A. K. (2024). Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy. International Journal of Molecular Sciences, 25(19), 10255. https://doi.org/10.3390/ijms251910255
Vancouver
Guevara-Ramírez P, Cadena-Ullauri S, Paz-Cruz E, Ruiz-Pozo VA, Tamayo-Trujillo R, Cabrera-Andrade A, et al. Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy. International Journal of Molecular Sciences. 2024;25(19):10255. doi:10.3390/ijms251910255
BibTeX
@article{GuevaraRamrez2024,
author = {Guevara-Ramírez, Patricia and Cadena-Ullauri, Santiago and Paz-Cruz, Elius and Ruiz-Pozo, Viviana A and Tamayo-Trujillo, Rafael and Cabrera-Andrade, Alejandro and Zambrano, Ana Karina},
title = {Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {19},
pages = {10255},
doi = {10.3390/ijms251910255}
}
EUVIMED